Esophageal Neoplasms Clinical Trial
Official title:
Phase II Study Comparing Radiochemotherapy With the Folfox 4 Regimen Versus Radiochemotherapy With 5FU-Cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Esophageal Cancer
NCT number | NCT00160030 |
Other study ID # | L_9326 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | September 9, 2005 |
Last updated | December 4, 2009 |
Start date | September 2004 |
The primary objectives of this study are to assess the feasibility (completion of full
treatment) in both arms and to assess endoscopic complete response rate in both arms.
The secondary objective of this study is to assess the toxicity profile of each arm using
the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) scale (V.3).
Status | Completed |
Enrollment | 97 |
Est. completion date | |
Est. primary completion date | October 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients with: - Histologically proven adenocarcinoma, squamous cell or adenosquamous carcinoma of the esophagus - Inoperable esophageal carcinoma (disease status: any T, N0 or N1, M0 or M1a) or surgical contraindication conditions - No prior treatment for esophageal cancer (surgery, laser, chemo- or radiotherapy) - Oesophageal dilatation is allowed before or during the treatment, but prior esophageal prosthesis is not allowed - Peripheral neuropathy <= NCI-CTC grade 1 - Age >= 18 years - Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2 - Sufficient (oral or with gastrostomy) calorific intake (> 1000 Kcal/m2/day) - Life expectancy >= 3 months - Adequate bone marrow reserve, normal renal and liver functions: - Neutrophil count >= 1500/mm³ - Platelet count >= 100,000/mm³ - Hemoglobin >= 10 g/dl (after transfusion, if necessary) - Creatinine levels <= 1.5 x the upper normal limit of institutional values (ULN) - Total bilirubin level < 1.5 x ULN - ALT/AST < 2.5 x ULN - Prothrombin time >= 60% - Laboratory values obtained the week preceding study entry - Signed informed consent (prior to all study procedures) - Start of treatment within 28 days of inclusion. Exclusion Criteria: - Metastatic disease except for third upper or cervical esophagus tumor with regional nodes, or third lower esophagus tumor with celiac nodes (M1a) - Multiple carcinomas of the esophagus - Small cell or undifferentiated carcinoma of the esophagus - Complete dysphagia (grade 4 NCI-CTC); patient with exclusive parenteral nutrition. - Weight loss > 20% normal body weight - Pregnant or breast-feeding women - Fertile patient not using adequate contraception - Peripheral sensitive neuropathy with functional impairment - Auditory disorders - History of prior malignancies (other than cured non melanoma skin cancer, cured cervical carcinoma in situ or stage I or II node negative head and neck cancer cured > 3 years ago) - Prior cervical, thoracic and abdominal radiotherapy with field overlapping the proposed oesophageal radiotherapy field - Tracheo-oesophageal fistula or invasion of the tracheo-bronchial tree - Previous myocardial infarction (inferior or equal to 6 months). Patients with a previous myocardial infarction superior to 6 months, could be included only if: no transient ischemia is shown by thallium myocardial scintigraphy and favourable advice for chemotherapy is obtained from a cardiologist. - Other serious illness or medical conditions (such as symptomatic coronary disease, left ventricular failure or uncontrolled infection) - Arterial disease stage II to IV according to the Leriche and Fontaine classification - Treatment with any other experimental drugs or participation in another clinical trial within 30 days of study screening - Concurrent treatment with any other anti-cancer therapy - Concurrent treatment with phenytoin and yellow fever vaccine; geographical, social or psychological circumstances preventing regular follow-up. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Sanofi-Aventis | Paris |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients having completed the full treatment and Endoscopic complete response rate | at the end of the study | No | |
Secondary | Toxicity profile (NCI-CTC). | evaluated each week | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05013697 -
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
|
Phase 2 | |
Completed |
NCT02128243 -
Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
|
Phase 2 | |
Completed |
NCT02253602 -
Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT01900691 -
Removal of the Evolution® Esophageal Stent - Fully Covered
|
N/A | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Terminated |
NCT01572987 -
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
|
N/A | |
Terminated |
NCT00760604 -
A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer
|
Phase 3 | |
Suspended |
NCT00048529 -
Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Completed |
NCT02284802 -
Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy
|
N/A | |
Terminated |
NCT03223662 -
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
|
Phase 2 | |
Completed |
NCT05680077 -
KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
|
||
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT03261947 -
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT00094978 -
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
|
Phase 1 | |
Recruiting |
NCT02908204 -
Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT02703142 -
Endoscopic Evaluation After Esophagectomy
|
N/A | |
Completed |
NCT02378948 -
Nutritional Route In Esophageal Resection Trial II
|
N/A | |
Recruiting |
NCT02604615 -
The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy
|
Phase 3 | |
Active, not recruiting |
NCT02279134 -
Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma
|
Phase 2/Phase 3 |